Renal Carcinoma clinical trials

Explore recruiting renal carcinoma clinical trials.

Recruiting renal carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-reported-outcome evaluation (CABOLD)

France

Therapeutic use (Phase IV) EU CTIS Study details

PAXIPEM : Multicenter phase II study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Italy, Czechia, Germany, Poland, Spain, Belgium +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

Czechia, Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study

France

Therapeutic use (Phase IV) EU CTIS Study details

Renal Carcinoma trials by city

Renal Carcinoma in Toronto Renal Carcinoma in Vancouver Renal Carcinoma in Montreal Renal Carcinoma in Calgary Renal Carcinoma in Edmonton Renal Carcinoma in Ottawa Renal Carcinoma in Winnipeg Renal Carcinoma in Quebec City Renal Carcinoma in Hamilton Renal Carcinoma in Kitchener Renal Carcinoma in London Renal Carcinoma in Halifax Renal Carcinoma in New York Renal Carcinoma in Los Angeles Renal Carcinoma in Chicago Renal Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease